Esophageal Squamous Cell Carcinoma: An Unfavorable Complication of Achalasia
American Journal of Gastroenterology
; 117(10 Supplement 2):S1561-S1562, 2022.
Article
in English
| EMBASE | ID: covidwho-2325463
ABSTRACT
Introduction:
Achalasia is a motility disorder of the esophagus characterized by impaired relaxation of the lower esophageal sphincter and loss of peristalsis in the distal esophagus. It is a rare condition with an annual incidence of 0.5-1.2 per 100,000 individuals. The etiology of primary achalasia is unknown, however secondary achalasia can be attributed to malignancy, infections or systemic diseases such as amyloidosis. An infrequent complication of achalasia is esophageal squamous cell carcinoma which has a prevalence of 26 in every 1,000 cases. We present a case of interval locoregionally advanced esophageal squamous cell carcinoma only 2 years after a normal upper endoscopy. Case Description/Methods:
A 67-year-old female with known achalasia and previous pneumatic dilation in her 30s presented to our outpatient clinic in 2019 with complaints of worsening chronic dysphagia. EGD was performed which revealed a significantly dilated esophagus with candida esophagitis. Despite completing antifungal therapy, she continued to experience dysphagia to solids and liquids. Barium swallow demonstrated absent peristalsis with pooling of contrast within the esophagus. High-Resolution Manometry testing demonstrated absent peristalsis. She opted for surgical myotomy, however due to COVID restrictions, the procedure was delayed. Repeat EGD was performed in 2022 for pre-surgical evaluation and showed a large obstructing friable esophageal mass in the lower third of the esophagus. Pathology was consistent with invasive poorly differentiated squamous cell carcinoma. PET scan showed locoregional disease with FDG-avid esophageal and gastrohepatic node lesions. She was started on chemoradiation with Paclitaxel and Carboplatin (Figure). Discussion(s) The risk of esophageal squamous cell carcinoma in achalasia has significantly increased with incidence of approximately 1 in 300 patients. The presumed mechanism of malignancy in achalasia is poor emptying resulting in food stasis, bacterial overgrowth and inflammation leading to dysplasia and development of carcinoma. Given the relatively low incidence, there are currently no guidelines on routine endoscopic screening to assess for malignancy in patients with achalasia. Survival rates are poor as patients are often diagnosed at advanced stages. This case aims to illustrate the importance and need for interval screening in individuals with long standing achalasia to improve outcomes.
advanced cancer; aged; antifungal therapy; bacterial overgrowth; cancer patient; cancer staging; cancer surgery; cancer survival; chemoradiotherapy; complication; conference abstract; coronavirus disease 2019; drug combination; drug therapy; dysphagia; dysplasia; endoscopy; esophageal squamous cell carcinoma; esophagography; esophagus achalasia; esophagus candidiasis; female; human; incidence; inflammation; major clinical study; manometry; myotomy; outpatient department; peristalsis; positron emission tomography; practice guideline; preoperative evaluation; prevalence; radiotherapy; squamous cell carcinoma; surgery; survival rate; carboplatin; paclitaxel; unclassified drug
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Etiology study
/
Experimental Studies
/
Observational study
/
Prognostic study
Language:
English
Journal:
American Journal of Gastroenterology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS